Table 1.

Description of recent experience with convalescent plasma therapy in COVID-19.

Number	Study	Country	Patients	Indications	ARDS	Survival	Highlights
1	Duan et al	China	10	Severe COVID 19	All	100%	Prospective study (for safety) Dose: One Volume: 200 ml Titers: 1: 640 Median time of illness to transfusion: 16.5 days No Severe Adverse effect 70% undetectable viral load Improvement in oxyhemoglobin, clinical symptoms, lymphocyte count, radiological findings Reduction in C reactive protein
2	Shen et al	China	5	Severe COVID19	All	100%	Prospective study (for efficacy) Dose: Twice Total volume: 400 ml Titers: 1:1000 Median time of illness to transfusion: 10-12 days Negative viral load in 12 days Increase in SARS-COV-2 specific ELISA and neutralizing antibody titer Improvement in fever (80%), ARDS (80%), PaO2/FiO2 ratio Weaning from ventilation (60%), discharge (60%) Reduction in SOFA score
3	Zhang et al	China	4	Severe COVID19	All	100%	Case series Maximum dose: 8 and 3 respectively Maximum volume: 900 ml Reduction in viral load Documented RT PCR negative status after treatment at discharge Improvement in clinical condition, lung imaging finding, and respiratory status
4	Ahn et al	Korea	2	Severe COVID19	All((	100%	Case reports Dose: 2 Volume: 500 ml On Hydroxychloroquine as well Measured Anti SARS – COV – 2 IgG antibody in donor plasma was: 0.586 Improvement in fever, imaging finding, respiratory parameters and clinical status Reduction in inflammatory markers including CRP, IL -6 and Viral load Documented negative viral RT PCR Weaned of ventilators and discharged
5	Ye et al	China	6	Moderate/SevereCOVID19	1	100%	Retrospective study Maximum doses: 3 Maximum volume: 600 ml Improvement in symptoms and radiological findings
6	Zeng et al	China	6	Severe COVID19	All	16%	Retrospective study Median dose: 2 Median volume: 300 ml Adverse effect: None SARS –COV-2 clearance documented in all patients (100%) SARS –COV-2 clearance documented in all patients before death (100%) Longer survival in patients receiving CP